Genmab A/S (NASDAQ:GMAB) – Equities researchers at Truist Securiti increased their FY2021 earnings per share (EPS) estimates for shares of Genmab A/S in a note issued to investors on Monday, October 11th. Truist Securiti analyst A. Goonewardene now anticipates that the company will earn $0.53 per share for the year, up from their previous estimate of $0.51. Truist Securiti also issued estimates for Genmab A/S’s Q4 2021 earnings at $0.09 EPS, FY2022 earnings at $0.62 EPS, FY2023 earnings at $0.85 EPS, FY2024 earnings at $1.46 EPS and FY2025 earnings at $2.24 EPS.
Other research analysts also recently issued reports about the company. HC Wainwright reissued a “hold” rating and issued a $47.00 price objective on shares of Genmab A/S in a research note on Monday, September 20th. Barclays reiterated an “overweight” rating on shares of Genmab A/S in a report on Thursday, August 12th. UBS Group restated a “neutral” rating on shares of Genmab A/S in a report on Thursday, August 12th. Societe Generale restated a “sell” rating on shares of Genmab A/S in a report on Monday, August 16th. Finally, Jefferies Financial Group cut shares of Genmab A/S from a “buy” rating to a “hold” rating and boosted their price target for the stock from $45.50 to $48.00 in a report on Thursday, September 16th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, Genmab A/S currently has a consensus rating of “Hold” and an average price target of $45.00.
Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Wednesday, August 11th. The company reported $0.08 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.08. Genmab A/S had a return on equity of 13.07% and a net margin of 34.37%. The firm had revenue of $319.48 million for the quarter, compared to analyst estimates of $268.28 million.
A number of large investors have recently added to or reduced their stakes in GMAB. Koshinski Asset Management Inc. acquired a new position in Genmab A/S during the 3rd quarter worth $73,000. Level Four Advisory Services LLC acquired a new stake in shares of Genmab A/S during the third quarter worth $376,000. Veriti Management LLC raised its position in Genmab A/S by 11.8% during the third quarter. Veriti Management LLC now owns 7,001 shares of the company’s stock valued at $306,000 after buying an additional 738 shares during the period. Lester Murray Antman dba SimplyRich increased its position in Genmab A/S by 1.0% in the 3rd quarter. Lester Murray Antman dba SimplyRich now owns 50,275 shares of the company’s stock worth $2,197,000 after purchasing an additional 481 shares during the last quarter. Finally, Bank of America Corp DE boosted its position in Genmab A/S by 25.7% during the second quarter. Bank of America Corp DE now owns 1,088,726 shares of the company’s stock worth $44,452,000 after purchasing an additional 222,776 shares during the period. Institutional investors and hedge funds own 7.01% of the company’s stock.
About Genmab A/S
Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia.
Read More: How does new data get added to a blockchain?
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.